Clinical trial
Retrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)
NCT04275388 is registered in ClinicalTrials.gov with Jiangxi Qingfeng Pharmaceutical Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Retrospective Cohort to Evaluate the Effectiveness and Safety of Xiyanping Injection Combined With Conventional Treatment for New Coronavirus Infection Pneumonia (Common Type)
- Lead sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- May 15, 2020
- Completion date
- December 14, 2021
- Enrollment
- 426 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
2019 novel coronavirus pneumonia